[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-and-lymphoid-system-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-and-lymphoid-system-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,41,62,80,100,165,188,218,247,266,293,310,336,358,379,398,422,443,464,484,503,523],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100540271","outreach-project-to-connect-underrepresented-populations-to-clinical-trials-at-ohio-state-university-cusp2ct-project-trial-100540271",false,"NCT06314672","Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial","The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) Project","Inclusion Criteria:\n\n* Phase I: 9 counties in the OSUCCC catchment area\n* Phase II: Patients, providers, and hospital systems\u002Freferral centers that directly addresses challenges identified in Phase I\n* Phase II: The project will involve the OSUCCC, the OSU James Cancer Network sites and the Columbus and Dayton NCORP sites",true,"ALL",{"count":19,"type":20},208,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial\u002Fethnic minorities. Progress in cancer prevention, detection and treatment can only be made by identifying and validating new and improved methods, compounds and modalities in clinical trials. Unfortunately, participation in clinical trials is not equal across all racial and ethnic groups, limiting progress against cancer in all population groups and further widening the disparity gap. To change this picture, concerted effort needs to be directed both at the communities at risk for being left out of trials and the systems that cause the disparities at all levels involved in accrual to clinical trials. The CUSP2CT project may have the potential to increase referral and accrual of racial\u002Fethnic minorities to prevention\u002Fcontrol and treatment trials.",[26,27],"Hematopoietic and Lymphoid System Neoplasm","Malignant Solid Neoplasm","RECRUITING","2026-06-05",{"date":31,"type":32},"2026-06-09","ACTUAL",{"date":34,"type":32},"2023-08-22",{"date":36,"type":20},"2028-12-31",{"name":38,"class":39},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":40},"100517314","group-cognitive-behavior-sessions-cbcsm-to-decrease-distress-in-cancer-patients-100517314","NCT06015932","Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients","A Non-Randomized Translational Trial of Cognitive Behavioral Cancer Stress Management (CBCSM) and Its Effects on Cancer Distress","Inclusion Criteria:\n\n* Eligible for the cognitive behavioral cancer stress management (CBCSM) clinical service\n* Cancer diagnosis with predicted survival \\> 1 year\n* Cancer treatment within past 1 year or treatment planning in progress\n* Age \\>= 18-years\n* Moderate distress screen, indicated by Impact of Event Scale-Revised (IES-R) score \\>= 14 or clinical judgment\n* Written informed research consent\n\nExclusion Criteria:\n\n* Inability to actively participate in and learn from group therapy (e.g., psychotic symptoms, neurological condition, personality pathology) as determined by clinical judgment in clinical consultation (Individual therapy or alternative group therapy will be offered)","18 Years",{"count":50,"type":20},400,[23],"This clinical trial tests how well cognitive behavioral cancer stress management (CBCSM) group sessions work to decrease psychological distress in cancer patients. CBCSM teaches patients how to recognize and reduce the impacts of cancer associated stress on the biological, psychological, and social life domains.",[26,27,54],"Metastatic Malignant Solid Neoplasm",{"date":31,"type":32},{"date":57,"type":32},"2017-12-20",{"date":59,"type":20},"2029-12-31",{"name":61,"class":39},"Mayo Clinic",{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":40},"100480036","examining-blood-and-tissue-samples-to-identify-diagnostic-markers-in-patients-with-metastatic-cancer-undergoing-tumor-removal-100480036","NCT05530759","Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal","Integrated Genomics and Patient-Derived Cancer Models","Inclusion Criteria:\n\n* Patients (or the legally authorized representative\u002Fguardian signing on behalf of the participant) must understand and provide written informed consent prior to initiation of any study-specific procedures\n* \\>= 18 years of age\n* Patients must have a diagnosis of confirmed malignancy\n* Patient is a good medical candidate for a standard of care biopsy or surgical procedure to obtain tissue or has archival tissue available for analysis\n\nExclusion Criteria:\n\n* Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent\n* Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use\n* Biopsy must not be considered to be more than minimal risk to the patient. Contraindications to percutaneous biopsy:\n\n  * Significant coagulopathy that cannot be adequately corrected\n  * Severely compromised cardiopulmonary function or hemodynamic instability\n  * Lack of a safe pathway to the lesion\n  * Inability of the patient to cooperate with, or to be positioned for, the procedure",{"count":70,"type":20},50,"OBSERVATIONAL","This study characterizes deoxyribonucleic acid (DNA) and proteomic (protein) changes in both biopsies and tumors removed during surgery of patients who have been diagnosed with aggressive\u002Fmetastatic (that has spread to other places in the body) cancer in order to identify possible diagnostic markers and potential drugs for treating aggressive tumor types. Proteomic analyses include looking at the proteome, or all the proteins expressed, or made by DNA at a specific moment in time. Studying samples of blood, buccal (cheek), and tissue in the laboratory from patients undergoing surgical resection or biopsy may help doctors learn more about the changes that occur in the proteome, DNA alterations, and identify molecular biomarkers for which therapeutic drugs may exist. Studying the DNA in tumor tissue and in blood may also help researchers see if the tumor has important differences.",[26,54],{"date":31,"type":32},{"date":76,"type":32},"2022-06-29",{"date":78,"type":20},"2031-04-30",{"name":61,"class":39},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100535063","acceptance-and-commitment-therapy-and-compassion-based-virtual-group-therapy-to-improve-psychological-wellbeing-in-patients-with-cancer-100535063","NCT06246955","Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer","\"Live Fully With Cancer\": Assessing the Impact of an Acceptance and Commitment Therapy and Compassion-Based Virtual Group Intervention for Diverse Cancer Patients","Inclusion Criteria:\n\n* Being an adult (18 years or older)\n* Being a patient of Mayo Clinic Arizona\n* Having a cancer diagnosis, having treatment planning in progress, undergoing cancer-related treatment, or having completed cancer within the past 2 years (in recent survivorship\n* Experiencing stress or challenges related to cancer and having treatment goals that align with the purpose of the group\n* Having self reported proficiency to read\u002Fwrite\u002Fspeak English\n* Expressing interest and commitment to attend all six virtual group sessions\n\nExclusion Criteria:\n\n* Patients' inability to take part in and benefit from the virtual group therapy based on clinical judgment of the psychosocial oncology team member who completes the psychosocial evaluation, which may include having active suicidal or homicidal intent, experiencing uncontrolled psychotic symptoms, having untreated personality disorder\u002Fcharacteristics that are likely disturbing in a group setting, and\u002For having moderate to severe cognitive impairments",{"count":88,"type":20},200,[23],"This clinical trial tests how well acceptance and commitment therapy and compassion based virtual group therapy works to improve psychological wellbeing, such as compassion, understanding, and flexibility, in patients with cancer. Receiving a cancer diagnosis, undergoing cancer treatment, and living with cancer- or treatment-related symptoms have often been found to be associated with elevated distress and decreased quality of life for individuals, even when the disease is stable or in remission. Acceptance and Commitment Therapy (ACT) has demonstrated considerable benefits on individuals' quality of life, psychological flexibility, and amelioration of psychological distress following a cancer diagnosis and in the face of uncertainty, loss, and challenges associated with cancer.",[26,27],"2026-05-28",{"date":94,"type":32},"2026-05-29",{"date":96,"type":32},"2024-01-08",{"date":98,"type":20},"2027-12-31",{"name":61,"class":39},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100513775","phase-2-at-home-cancer-directed-therapy-versus-in-clinic-for-the-treatment-of-patients-with-advanced-cancer-100513775","NCT05969860","At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic","Inclusion Criteria:\n\n* Female or male patients with histologically confirmed malignancy. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis along; histologic confirmation is not required.\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) FDA-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines.\n\n  * Note, patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Patients may receive any combination of any above listed medications or regimens:\n  * Eligible disease cancer types:\n\n    * Anal cancer\n    * Appendiceal carcinoma\n    * Basal cell carcinoma\n    * Bladder cancer\n    * Biliary cancer\n    * Breast cancer\n    * Central Nervous System malignancy including glioblastoma\n    * Cervical cancer\n    * Cholangiocarcinoma\n    * Colorectal carcinoma\n    * Endometrial cancer\n    * Fallopian tube cancer\n    * Gastroesophageal cancer \\[including gastric, esophageal, and gastroesophageal junction (GEJ) cancers\\]\n    * Germ cell carcinoma\n    * Head and Neck cancer\n    * Hepatocellular Carcinoma\n    * Liver\n    * Lung\n    * Lymphoma\n    * Melanoma\n    * Merkel Cell\n    * Multiple Myeloma\n    * Myelodysplastic syndrome\n    * Myeloid Disorders\n    * Neuroendocrine carcinoma\n    * Ovarian cancer\n    * Pancreatic adenocarcinoma\n    * Penile carcinoma\n    * Peritoneal carcinoma\n    * Prostate cancer\n    * Renal cell cancer\n    * Sarcoma\n    * Squamous cell Carcinoma of the Skin\n    * Testicular cancer\n    * Urethral carcinoma\n    * Vaginal carcinoma\n    * Vulvar carcinoma\n  * Eligible Regimens\n\n    * Fluorouracil (5-FU) +\u002F- leucovorin +\u002F- bevacizumab +\u002F- trastuzumab\n    * 5FU +\u002F- leucovorin +\u002F- bevacizumab +\u002F- nivolumab\n    * Atezolizumab +\u002F- bevacizumab\n    * Atezolizumab +\u002F- bevacizumab + cobimetinib, atezolizumab +\u002F- bevacizumab + vemurafenib, atezolizumab +\u002F- bevacizumab + cobimetinib + vemurafenib\n    * Avelumab\n    * Avelumab + axitinib\n    * Bevacizumab\n    * Bevacizumab + capecitabine\n    * Bevacizumab + irinotecan (+\u002F- capecitabine)\n    * Bevacizumab + olaparib, bevacizumab + lenvatinib, bevacizumab + niraparib, bevacizumab + rucaparib\n    * Bevacizumab + Temozolomide, Bevacizumab + Lomustine, or Bevacizumab + everolimus\n    * Bevacizumab + trifluridine\u002Ftipiracil\n    * Bortezomib\n    * Bortezomib + cyclophosphamide, bortezomib + lenalidomide, bortezomib + pomalidomide, bortezomib + selinexor\n    * Bortezomib + venetoclax\n    * Carfilzomib\n    * Carfilzomib + cyclophosphamide, carfilzomib + lenalidomide, carfilzomib + pomalidomide, carfilzomib + selinexor\n    * Carfilzomib + venetoclax\n    * Cemiplimab\n    * Cisplatin\n    * Cisplatin\u002F5-FU\n    * Cisplatin\u002Fetoposide\n    * Cisplatin + durvalumab\n    * Cisplatin + gemcitabine\n    * Cisplatin + gemcitabine + durvalumab\n    * Daratumumab (+ oral \\[PO\\] cyclophosphamide, lenalidomide, pomalidomide, or selinexor)\n    * Daratumumab + bortezomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)\n    * Daratumumab + carfilzomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)\n    * Degarelix\n    * Durvalumab\n    * Durvalumab + tremelimumab\n    * Eribulin\n    * FOLFIRI +\u002F- bevacizumab (5FU +\u002F- leucovorin + irinotecan)\n    * Fam-trastuzumab deruxtecan\n    * Fulvestrant\n    * Fulvestrant + ribociclib, fulvestrant + abemaciclib, fulvestrant + palbociclib, fulvestrant + alpelisib, or fulvestrant + capivasertib\n    * Gemcitabine\n    * Gemcitabine + durvalumab\n    * Gemcitabine + paclitaxel protein-bound\n    * Goserelin acetate\n    * Irinotecan\n    * Irinotecan + capecitabine\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + cabozantinib\n    * Nivolumab-relatlimab\n    * Octreotide\n    * Paclitaxel\n    * Pembrolizumab\n    * Pembrolizumab + axitinib, pembrolizumab + lenvatinib, pembrolizumab + capecitabine, pembrolizumab + dabrafenib +\u002F- trametinib, pembrolizumab + trametinib)\n    * Pemetrexed\n    * Pertuzumab\n    * Pemetrexed + pembrolizumab\n    * Rituximab\n    * Trastuzumab + paclitaxel\n    * Trastuzumab with or without pertuzumab maintenance (SQ or IV) (+\u002F- tucatinib +\u002F- capecitabine)\n    * Decitabine\n    * These regimens can be used only if patients are receiving one of the regimens above:\n\n      * Darbepoetin-alfa\n      * Epoetin\n      * Filgrastim\n* Note: Female or male patients with histologically confirmed malignancy who are currently receiving treatment with one of the above eligible regimens may receive supportive care medications for treatment or prevention of bone metastases, including agents such as:\n\n  * Zoledronic acid\n  * Denosumab\n* Patient has had adequate tolerability of their clinical standard of care cancer treatment in the opinion of their treating physician and no drug-related infusion reactions prior to consent\n* Patients who according to documentation from their treating provider plan to continue the treatment regimen they are currently prescribed for at least 24 weeks from the start of cycle following randomization.\n* Residing within the area serviced by supplier and paramedic network\n* Residence has wireless fidelity (wifi) to enable a reliable connection with the remote Command Center or it is suitable for connection through a wireless network solution\n* Age \\>= 18 years at time of registration\n* Signed informed consent form by patient\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2\n* Ability to complete questionnaire(s) by themselves or with assistance\n* RANDOMIZATION ELIGIBILITY CRITERIA: In addition to the criteria above, confirmation by the CCBW Command Center that the patient has adequate tolerability to the standard of care cancer therapy and no drug-related infusion reactions since pre-registration and prior to registration\n\nExclusion Criteria:\n\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm. Note: Patients are permitted concomitant standard of care oral drugs such as ribociclib, abemaciclib, or palbociclib in combination with endocrine therapy (e.g., Leuprolide, fulvestrant intramuscular \\[IM\\], etc.); tucatinib and capecitabine in combination with trastuzumab and pertuzumab for HER2 positive breast cancer; dexamethasone, cyclophosphamide, lenalidomide or pomalidomide for multiple myeloma; temozolomide, lomustine, or afinitor in combination with avastin for glioblastoma. In addition, all oral anti-hormonal agents for breast and prostate cancer are permitted (e.g., tamoxifen, arimidex, abiraterone, etc.) if used in combination with any of the drugs\n* Requiring 24\u002F7 assistance with activities of daily living (ADLs)\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Myocardial infarction =\\\u003C 6 months\n  * Wound healing disorder\n  * Or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",{"count":108,"type":20},220,[110],"PHASE2","This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and financial burden for patients and their families. The logistics and costs of navigating cancer treatments have become a principal contributor to patients' reduced quality of life. It is therefore important to reduce the burden of cancer in the lives of patients and their caregivers, and a vital aspect of this involves moving beyond traditional hospital and clinic-based care and evaluate innovative care delivery models with virtual capabilities. Providing cancer treatment at-home, versus in the clinic, may help reduce psychological and financial distress and increase treatment compliance, especially for marginalized patients and communities.",[113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,26,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155],"Advanced Anal Carcinoma","Advanced Biliary Tract Carcinoma","Advanced Bladder Carcinoma","Advanced Breast Carcinoma","Advanced Carcinoid Tumor","Advanced Cervical Carcinoma","Advanced Colorectal Carcinoma","Advanced Gastric Carcinoma","Advanced Glioblastoma","Advanced Head and Neck Carcinoma","Advanced HER2 Positive Breast Carcinoma","Advanced Lung Carcinoma","Advanced Lung Small Cell Carcinoma","Advanced Malignant Germ Cell Tumor","Advanced Malignant Solid Neoplasm","Advanced Neuroendocrine Carcinoma","Advanced Ovarian Carcinoma","Advanced Pancreatic Carcinoma","Advanced Prostate Small Cell Neuroendocrine Carcinoma","Advanced Prostate Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Advanced Basal Cell Carcinoma","Advanced Cholangiocarcinoma","Advanced Endometrial Carcinoma","Advanced Esophageal Carcinoma","Advanced Fallopian Tube Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Liver Carcinoma","Advanced Lymphoma","Advanced Malignant Testicular Neoplasm","Advanced Melanoma","Advanced Merkel Cell Carcinoma","Advanced Penile Carcinoma","Advanced Primary Malignant Central Nervous System Neoplasm","Advanced Renal Cell Carcinoma","Advanced Sarcoma","Advanced Skin Squamous Cell Carcinoma","Advanced Urethral Carcinoma","Advanced Vaginal Carcinoma","Advanced Vulvar Carcinoma","Advanced Appendix Carcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","2026-04-15",{"date":158,"type":32},"2026-04-20",{"date":160,"type":32},"2023-08-23",{"date":162,"type":20},"2027-01-01",{"name":61,"class":39},2,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100531300","a-collaborative-intervention-for-improving-cancer-pain-management-in-cancer-survivors-100531300","NCT06198010","A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors","Advancing Safe, Comprehensive, Digitally-Enabled Cancer Pain managemeNT (ASCENT)","ASCENT","Inclusion Criteria:\n\n* A qualifying liquid or solid cancer diagnosis with visits at a participating Mayo site in the past 15 years\n\n  * Including malignant hematology\n\n    * Lymphoma\n    * Myeloma\n    * Chronic leukemias\n* Age \\>= 18\n* Numeric Rating Scale (NRS) pain score of \\>= 5\u002F10\n* Pain that developed or worsened following cancer diagnosis\n* Fit the description of either rural or Hispanic or both\n\nExclusion Criteria:\n\n* Patient Health Questionnaire - 8 (PHQ8) score of \\>= 13\n* Hospice enrollment\n* Skilled nursing facility, inpatient rehabilitation facility, or long-term care placement\n* Encounters with Palliative Care or the Pain Clinic in the past two months or upcoming two months\n* Any mention of hospice referral in medical oncology encounter notes (assess through textual search of the Mayo Data Explorer)\n* Affirmative response to, \"Are you usually confined to a bed or chair more than a third of your waking hours because of your health?\"\n* Currently homeless\n* Do not feel safe in their home\n* New or worsening chest pain, chest tightness, or chest pressure\n* Back pain that is associated with a new or worsening weakness, control of bowels\u002Fbladder, or difficulty walking\n* Lightheadedness, inability to keep down food or fluids, or vomiting blood or dark coffee-grounds-like material\n* New or worsening headaches that are associated with vision changes, nausea, balance issues, or problems with speech\n* Screens positive for use of non-cannabis drug use a a frequency of monthly or greater\n* Inability to engage with the intervention due to medical or psychological response",{"count":174,"type":20},660,[23],"This clinical trial tests a collaborative pain management intervention (ASCENT) for improving cancer pain in cancer survivors. Cancer pain is prevalent, under-treated, and remains a major cause of suffering, impairment, and disability for millions of Americans. Individual pain interventions and care models show promise for cancer pain in controlled settings. All cancer survivors stand to benefit from electronic health record innovations, as they can experience profound pain outcomes, including marked under- and over-prescribing of opioids. Digitally facilitated solutions are especially helpful and can be customized to address patient needs. The ASCENT intervention provides patients with an educational guide that describes techniques for addressing cancer pain, and uses community health workers and pain care managers to coach patients through a personalized pain management plan. This study may help researchers learn how pain management strategies can improve cancer pain and lower risk of opioid exposure and dependency in cancer survivors.",[26,27,178],"Hematopoietic and Lymphatic System Neoplasm","2026-04-08",{"date":181,"type":32},"2026-04-13",{"date":183,"type":32},"2024-02-07",{"date":185,"type":20},"2027-08-31",{"name":61,"class":39},3,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":196,"targetDuration":198,"studyType":71,"phases":4,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":187},"100516735","interogating-cancer-for-etiology-prevention-and-therapy-navigation-100516735","NCT06008392","INTERogating Cancer for Etiology, Prevention and Therapy Navigation","INTERogating Cancer for Etiology, Prevention and Therapy Navigation (INTERCEPTioN)","INTERCEPTioN","Inclusion Criteria:\n\nGROUP A: Germline and Somatic Testing\n\n* Has Mayo Clinic medical record number\n* Confirmed cancer diagnosis\n* Germline and\u002For somatic tumor\u002Fblood testing has been ordered by the clinical provider (or clinical delegate)\n* Participant aware of cancer diagnosis\n* Able to provide informed consent\n* ≥ 18 years old\n* Ability to provide blood, saliva, bone marrow aspirate or hair follicle sample\n* Ability to provide archived tissue, if somatic testing has not already been completed\n\n  * Note: if tissue unavailable participant may still enroll onto the study for the germline collection, or vice versa, if germline has already been completed may still enroll for somatic tissue\u002Fblood testing.\n\nGROUP B: Germline testing only:\n\n* Has Mayo Clinic medical record number\n* Confirmed cancer diagnosis\n* Germline testing has been ordered by the clinical provider (or clinical delegate)\n* Participant aware of cancer diagnosis\n* Able to provide informed consent\n* ≥ 18 years old\n* Ability to provide blood, saliva, or hair follicle sample\n\nGROUP C: Somatic tumor testing only:\n\n* Has Mayo Clinic medical record number,\n* Confirmed cancer diagnosis,\n* Somatic tumor\u002Fblood testing has been ordered by the clinical provider (or clinical delegate)\n* Participant aware of cancer diagnosis,\n* Able to provide informed consent,\n* ≥ 18 years old\n* Ability to provide archived tissue or blood for somatic tumor genomic profiling, if not already completed.\n\nGroup D: Clinical standard of care germline testing via genetic counselor:\n\n* Has Mayo Clinic medical record number,\n* Standard of care clinical visit with genetic counselor\n* Confirmed cancer diagnosis,\n* Germline testing has been ordered by the clinical provider (or clinical delegate)\n* Participant aware of cancer diagnosis,\n* Able to provide informed consent,\n* ≥ 18 years old\n* Ability to provide blood, saliva, or hair follicle sample\n\nGroup E: Previous Enrollment in IRB #24-005734, 24-000609, 25-000815, 23-001689, or 24-004810:\n\n* Enrolled in any of the following studies: IRB #24-005734, 24-000609, 25-000815, 23-001689, or 24-004810\n* Completed Riskguard, OncoExtra, Caris Assure, or Caris MI Profile or any combination of these tests.\n* Has Mayo Clinic medical record number,\n* Confirmed cancer diagnosis,\n* Participant aware of cancer diagnosis\n* Able to provide informed consent,\n* ≥ 18 years old\n\nExclusion Criteria:\n\nNote: Women who are pregnant or planning to become pregnant can take part in this study.\n\nGROUP A: Germline and Somatic testing\n\n* Individuals who have situations that would limit compliance with the study requirements\n* Institutionalized (i.e. Federal Medical Prison)\n\nGROUP B: Germline testing only\n\n* Individuals who have situations that would limit compliance with the study requirements\n* Institutionalized (i.e. Federal Medical Prison)\n* Prior germline genetic testing with a 100+ multi-gene panel within the last 1 year of enrollment\n\nGroup C: Somatic tumor testing only:\n\n* Individuals who have situations that would limit compliance with the study requirements,\n* Institutionalized (i.e. Federal Medical Prison),\n\nGroup D: Clinical standard of care germline testing via genetic counselor:\n\n* Individuals who have situations that would limit compliance with the study requirements,\n* Institutionalized (i.e. Federal Medical Prison)\n\nGroup E: Previous Enrollment in IRB #24-005734, 24-000609, 25-000815, 23-001689, or 24-004810:\n\n* Individuals who have situations that would limit compliance with the study requirements,\n* Institutionalized (i.e. Federal Medical Prison)",{"count":197,"type":20},500,"50 Years","This study is being done to identify markers and causes of cancer by analyzing patient's DNA (i.e., genetic material), RNA, plasma, tissues, or other samples that could be informative for patients with cancer. Cancer genetic testing is a series of tests that finds specific changes in cancer cells and normal cells in the body. Researchers may request to access these data as they explore how to better prevent, screen, or treat cancer. This study is also being done to create a biobank (library) of samples and information to learn more about treating cancer. Discovery of genetic variants in patients with cancer could result in opportunities for cancer prevention, earlier diagnosis or better therapy for cancer.",[201,202,203,26,27],"Cancer","Cancer Gene Mutation","PAN Gene Mutation",[205,206,207,208,209],"Whole Exome Sequencing (WES)","Whole Genome Sequencing (WGS)","Genetic Testing","Genetic Counseling","Genomics","2026-04-06",{"date":212,"type":32},"2026-04-07",{"date":214,"type":32},"2023-10-12",{"date":216,"type":20},"2033-09",{"name":61,"class":39},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":234,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":40},"100609963","virtual-reality-intervention-to-improve-psychological-symptom-burden-for-cancer-patients-undergoing-treatment-100609963","NCT07221409","Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment","Pilot Study to Assess Safety, Tolerability and Efficacy of Virtual Reality in Cancer Patients","Inclusion Criteria:\n\n* History of cancer\n* Age between 18 to 90 years\n* Undergoing in-patient chemotherapy, bone marrow transplant (BMT), chimeric antigen receptor (CAR)-t, \\& out-patient chemotherapy\n\nExclusion Criteria:\n\n* History of bipolar disorder, major depression, bipolar disorder, anxiety disorder, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), psychotic disorder, schizophrenia, personality disorder, substance use disorder other than caffeine or tobacco. History of suicidal ideation or attempt\n* History of treatment resistant depression, psychiatric hospitalization, syncope, transient ischemic attack (TIA), stroke, epilepsy, electroconvulsive therapy, benign positional vertigo, Meniere's disease","90 Years",{"count":227,"type":20},24,[23],"This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.",[231,232,233,26,27,201],"Adjustment Disorder","Anxiety Disorder","Depression",[235,236,237,238],"Virtual Reality Therapy","VR Therapy","Non-Pharmacologic Intervention","Cancer Supportive Care","2026-03-31",{"date":241,"type":32},"2026-04-02",{"date":243,"type":32},"2025-10-08",{"date":245,"type":20},"2027-10-08",{"name":61,"class":39},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":164},"100506378","communication-issues-in-patient-and-provider-discussions-of-immunotherapy-100506378","NCT05873608","Communication Issues in Patient and Provider Discussions of Immunotherapy","Communication Issues in Patient\u002FProvider Discussions of Immunotherapy","Inclusion Criteria:\n\n* AIMS 1-3: All patients and providers who may have a discussion about immunotherapy at the Winship Cancer Institute\n* AIM 4: Any cancer patient",{"count":255,"type":20},125,[23],"This trials studies communication issues in patient and provider discussions about immunotherapy. The goal of this study is to describe where patients have heard about immunotherapy, what the participants understand about it, how physicians and other healthcare workers describe immunotherapy, and how educational videos may support patient knowledge about immunotherapy.",[26,27],{"date":210,"type":32},{"date":261,"type":32},"2016-10-06",{"date":263,"type":20},"2027-11-17",{"name":265,"class":39},"Emory University",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100321927","phase-1-ivosidenib-and-venetoclax-with-or-without-azacitidine-in-treating-patients-with-idh1-mutated-hematologic-malignancies-100321927","NCT03471260","Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies","Phase Ib\u002FII Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +\u002F- Azacitidine in IDH1-Mutated Hematologic Malignancies","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. ECOG performance status of \\\u003C 2.\n3. IDH1-R132 mutated disease status as assessed by local laboratory. 2HG-producing IDH1 variants outside of R132 (i.e. R100) may be eligible after discussion with the PI.\n4. Relapsed\u002Frefractory AML, or treatment-naïve patients with AML who are not eligible for standard induction chemotherapy. Patients with high-risk MDS, MDS\u002FMPN or MPN (defined as \\> 10% bone marrow blasts, or intermediate or high risk by IPSS, R-IPSS or D-IPSS) that have failed standard therapy may also be eligible after discussion with the PI.\n5. Adequate hepatic function (direct bilirubin \\\u003C 2 x ULN, ALT and\u002For AST \\\u003C 3x ULN) unless deemed to be related to underlying leukemia.\n6. Adequate renal function including creatinine clearance \\> 30 ml\u002Fmin based on the Cockcroft-Gault equation.\n7. Willing and able to provide informed consent\n8. In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents.\n9. Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Patients with known allergy or hypersensitivity to ivosidenib or venetoclax.\n2. Patients who have previously received either ivosidenib or venetoclax.\n3. Patients with any concurrent uncontrolled clinically significant medical condition including infection, laboratory abnormality, or psychiatric illness, which could place the patient at unacceptable risk of study treatment.\n4. The use of other chemotherapeutic agents or anti-leukemic agents is not permitted during study with the following exceptions (1) intrathecal chemotherapy for prophylactic use or for controlled CNS leukemia. (2) use of hydroxyurea and\u002For one dose of cytarabine (up to 2 g\u002Fm2) for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.\n5. Patients receiving concomitant strong CYP3A inducers (avasimibe, carbamazepine, phenytoin, rifampin, rifabutin, St. John's wort) within 3 days of start of study therapy.\n6. Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and\u002For phototherapy for chronic skin GVHD are permitted after discussion with the PI).\n7. Patients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications.\n8. Patients with a concurrent active malignancy under treatment.\n9. QTc interval using Fridericia's formula (QTcF) \\> 450 msec. Bundle branch block and prolonged QTc interval are permitted after discussion with the PI.\n10. Known active hepatitis B (HBV) or Hepatitis C (HCV) infection or known HIV infection.\n11. Subject has a white blood cell count \\> 25 x 10⁹\u002FL. (Note: Hydroxyurea is permitted to meet this criterion.)\n12. Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception a. Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, IUD, and double barrier methods (for example a condom in combination with a spermicide).",{"count":274,"type":20},96,[276,110],"PHASE1","This phase Ib\u002FII trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating patients with hematologic malignancies compared to ivosidenib and venetoclax alone.",[279,26,134,280,281,282],"Acute Myeloid Leukemia","Myeloproliferative Neoplasm","Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","2026-03-10",{"date":285,"type":32},"2026-03-11",{"date":287,"type":32},"2018-03-19",{"date":289,"type":20},"2027-09-30",{"name":291,"class":39},"M.D. Anderson Cancer Center",4,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":40},"100530906","a-novel-molecular-approach-to-blood-dna-screening-for-cancer-specificity-assessment-the-nomad-study-100530906","NCT06192875","A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)","Inclusion Criteria:\n\n* 10,000 patients without a known internal (non-cutaneous) cancer or a history of an internal cancer\n\n  * To balance age, rough recruitment goals will be set for the following subsets: 18-39 years, 40-49 years , 50-59 years , 60-69 years , 70-79 years , and \\>= 80 years\n  * To balance sex, roughly half of the participants recruited within each age subset will be women\n  * Roughly half of all participants will have had a colonoscopy or colon x-ray within the past 5 years, or Cologuard® test in the last 3 years which were negative for cancer and precancerous lesions\n  * Roughly half of all participants will have had a chest x-ray within the past 5 years which was negative for cancer\n  * Roughly half of women participants will have had a mammography in the past 5 years which was negative for cancer\n  * An attempt will be made to recruit minimums (parentheses) of the following subsets: men with normal Prostate-specific antigen (PSA) level (200); diabetes mellitus (200); connective tissue diseases like rheumatoid arthritis, systemic lupus erythematosus, and scleroderma (100); chronic obstructive lung disease (100); inflammatory bowel disease or cirrhosis (100), and pancreatitis (100)\n  * To assess the effects of other common covariates, specific recruitment targets will not be set. Rather, data obtained on all participants will include BMI, smoking (past\u002Fpresent), alcohol consumption, pregnant status (women), and selected medications (steroidal and non-steroidal anti-inflammatory drugs, statins, anti-hypertensives, and anti-depressants)\n\nExclusion Criteria:\n\n* Patients has a past or current diagnosis of invasive cancer (this does not include basal cell or squamous cell skin cancers)\n* Patient has had a solid organ transplant\n* Inability to give informed consent\n\nURINE EXCLUSIONS\n\n* Patient has transurethral instrumentation (cystoscopy, placement of urinary catheter) within the 7 days prior to sample collection\n* Patient has chronic indwelling urinary catheter\n* Patient has had a urinary tract infection within the 14 days prior to sample collection\n\nSALIVA EXCLUSIONS\n\n* Patient has known clinically significant xerostomia\n* Patient has known recent (within 30 days prior to collection) active upper respiratory tract infection or anogenital infection",{"count":300,"type":20},10000,"This study is being done to establish \"normal' values for a new blood test and urine test approach to cancer screening. Patients undergo blood and urine sample collection on study. Patients' medical records are reviewed.",[26,27],"2026-03-06",{"date":283,"type":32},{"date":306,"type":32},"2015-09-28",{"date":308,"type":20},"2035-12",{"name":61,"class":39},{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":21,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":187},"100520655","phase-2-cmv-mva-triplex-vaccination-in-hla-matched-related-stem-cell-donors-for-the-prevention-of-cmv-infection-in-patients-undergoing-hematopoietic-stem-cell-transplant-100520655","NCT06059391","CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* DONORS: Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* DONORS: Age: 18 and above\n* RECIPIENTS: Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* RECIPIENTS: Participant must be willing to comply with study and\u002For follow-up procedures, including willingness to be followed for one year post-HCT\n* RECIPIENTS: Age: 18 and above\n* RECIPIENTS: Karnofsky performance score ≥ 70 or ECOG ≤ 2\n* RECIPIENTS: Planned HCT for the treatment of the following hematologic malignancies: lymphoma (Hodgkin and Non-Hodgkin), myelodysplastic syndrome, acute lymphoblastic leukemia in first or second remission, acute myeloid leukemia in first or second remission, chronic myelogenous leukemia (in first chronic or accelerated phase, or in second chronic phase), chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma are excluded\n* RECIPIENTS: CMV seropositive\n* RECIPIENTS: Planned related HCT with 8\u002F8 (A, B, C, DRB1) high resolution human leukocyte antigen (HLA) donor allele matching\n* RECIPIENTS: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted. Patients may receive myeloablative, reduced intensity, or nonmyeloablative conditioning\n* RECIPIENTS: Total bilirubin ≤ 2 X upper limit of normal (ULN) (unless has Gilbert's disease)\n* RECIPIENTS: Aspartate aminotransferase (AST) ≤ 2.5 x ULN\n* RECIPIENTS: Alanine aminotransferase (ALT) ≤ 2.5 x ULN\n* RECIPIENTS: Creatinine clearance of ≥ 60 mL\u002Fmin per 24 hour urine test or the Cockcroft-Gault formula\n* RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50% Note: To be performed within 45 days prior to day 1 of protocol therapy\n* RECIPIENTS: If able to perform pulmonary function tests: forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin). If unable to perform pulmonary function tests: oxygen (O2) saturation \\> 92% on room air Note: To be performed within 45 days prior to day 1 of protocol therapy\n* RECIPIENTS: Seronegative for human immunodeficiency virus (HIV) antigen (Ag)\u002Fantibody (Ab) combo, hepatitis C virus (HCV)\\*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin \\[RPR\\])\n\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable\n* RECIPIENTS: Meets other institutional and federal requirements for infectious disease titer requirements Note: Infectious disease testing to be performed within 45 days prior to day 1 of protocol therapy\n* RECIPIENTS: Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* RECIPIENTS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and for up to 90 days post-HCT.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* DONORS: Any prior transplant to day 1 of protocol therapy\n* DONORS: Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy\n* DONORS: Receipt of any vaccine (licensed or investigational) within 30 days prior to and after of the study vaccine\n* DONORS: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension\n* DONORS: Sickling hemoglobinopathy including hemoglobin S (HbSS), sickle cell trait (HbAS), hemoglobin sickle C disease (HbSC)\n* DONORS: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus bradycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination\n* DONORS: Positive for HIV, active hepatitis B (HBV), hepatitis C (HCV) or human T-cell lymphotropic virus (HTLV-I\u002FII)\n* DONORS: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely, and making informed consent impossible\n* DONORS: Females only: Pregnant or breastfeeding\n* DONORS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* DONORS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)\n* RECIPIENTS: Any prior investigational CMV vaccine\n* RECIPIENTS: Experimental anti-CMV chemotherapy in the last 6 months\n* RECIPIENTS: Prior allogeneic (allo) transplant for any condition\n* RECIPIENTS: Live attenuated vaccines\n* RECIPIENTS: Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections)\n* RECIPIENTS: Allergy treatment with antigens injections\n* RECIPIENTS: Alemtuzumab or any equivalent in vivo T-cell depleting agent\n* RECIPIENTS: Antiviral medications with known therapeutic effects on CMV such as valganciclovir\u002Fganciclovir (GCV\u002FVAL), foscarnet (FOS), cidofovir, brincidofovir (CMX-001), maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)\n* RECIPIENTS: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment\n* RECIPIENTS: Other investigational product - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited\n* RECIPIENTS: Other medications that might interfere with the evaluation of the investigational product\n* RECIPIENTS: Diagnosis with autoimmune disease\n* RECIPIENTS: Females only: Pregnant women and women who are lactating. The risks of Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study\n* RECIPIENTS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* RECIPIENTS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","75 Years",{"count":319,"type":20},216,[110],"This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem cell transplant. Giving the CMV-MVA triplex vaccine to donors may help prevent CMV infection of patients undergoing stem cell transplantation.",[323,279,324,325,26,326,134,327,280,328],"Acute Lymphoblastic Leukemia","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Hodgkin Lymphoma","Myelofibrosis","Non-Hodgkin Lymphoma",{"date":283,"type":32},{"date":331,"type":32},"2024-07-12",{"date":333,"type":20},"2029-01-01",{"name":335,"class":39},"City of Hope Medical Center",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":40},"100527743","evaluation-of-hypertension-management-and-cardiovascular-adverse-event-prevention-in-patients-with-b-cell-malignancies-undergoing-treatment-with-bruton-tyrosine-kinase-inhibitors-the-halt-study-100527743","NCT06151730","Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study","Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study","Inclusion Criteria:\n\n* Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up\n\nExclusion Criteria:\n\n* Patients with known central nervous system (CNS) involvement of their B-cell malignancy",{"count":344,"type":20},100,"This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.",[324,26,347,348,349],"Mantle Cell Lymphoma","Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia","2026-02-24",{"date":352,"type":32},"2026-02-27",{"date":354,"type":32},"2024-01-05",{"date":356,"type":20},"2026-06-30",{"name":61,"class":39},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":21,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":40},"100484162","group-curriculum-for-improving-survivorship-outcomes-in-adolescent-and-young-adult-cancer-survivors-100484162","NCT05584449","Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors","Determining the Impact of a Curriculum for a Cancer Survivorship Group for Adolescents and Young Adults (AYA)","Inclusion Criteria:\n\n* Age 18-39\n* Is a patient of Mayo Clinic Arizona for oncologic care and\u002For follow-up\n* History of cancer diagnosis\n* Treated with curative intent\n* Completed cancer treatment within 6 months to 2 years prior to group attendance\n* Ability to read\u002Fwrite\u002Fspeak English\n* Ability to participate in a group setting\n* Ability to commit to attending all six group meetings\n\nExclusion Criteria:\n\n* Inability to read\u002Fwrite\u002Fspeak English\n* No internet or computer access\n* Not receiving care at Mayo Clinic Arizona\n* Currently receiving treatment for cancer\n* Is unable to sit comfortably for 90 minutes\n* Was not treated with curative intent\n* Is on hospice care\n* Co-morbid systemic illness or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessments","39 Years",{"count":367,"type":20},60,[23],"This clinical trial studies the effectiveness of a group curriculum in improving survivorship outcomes in adolescent and young adult (AYA) cancer survivors. Many AYA survivors typically do not feel prepared to re-enter \"daily life\" and would likely benefit from structured interventions to offer education and support in a timely manner as to prepare them for the challenges of life in survivorship. A 6-week group curriculum, designed to specifically meet the needs of AYA cancer survivors and facilitated by licensed social workers, may meet the unique needs of young adults who have survived a cancer diagnosis, and if so, the curriculum could be licensed and used across Mayo Clinic sites and potentially at other cancer centers nationwide.",[26,27],"2026-01-29",{"date":373,"type":32},"2026-01-30",{"date":375,"type":32},"2023-01-16",{"date":377,"type":20},"2027-10-18",{"name":61,"class":39},{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":40},"100470873","assessing-effect-of-spinal-cord-stimulation-on-pain-and-quality-of-life-with-chemotherapy-induced-peripheral-neuropathy-100470873","NCT05411523","Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy","A Prospective Observational Study Assessing Efficacy of 10-kHz Spinal Cord Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adult patients greater than or equal to 18 years of age who have been clinically diagnosed with CIPN for greater than six months after stopping chemotherapy\n* Average pain intensity \\>= 5 on 11-point numeric rating scale (NRS) in the lower extremities at enrollment\n* Failed conventional medication management with at least two neuropathic pain medications\n* Have electrophysiological evidence of length-dependent peripheral neuropathy\n* Underwent a 10-kHz spinal cord stimulator trial for a primary indication of CIPN and reported a successful trial of at least 75% reduction in pain intensity\n* Have stable neurological status\n* Be on a stable analgesic regimen\n* Be an appropriate candidate for surgical procedures required in this study\n* Be able to read and understand English-written questionnaires and sign an informed consent form in English\n* Be willing and capable of giving informed consent\n* Be willing and able to complete study-related requirements, procedures, and visits\n\nExclusion Criteria:\n\n* Patient refusal to be included in study\n* Presence of lower limb mononeuropathy\n* History of lower limb amputation or ulceration\n* Presence of another painful condition that is unrelated to CIPN and that is not intended to be treated in this study\n* Body mass index (BMI) \\>= 40\n* Omeprazole (OME) \\> 120 mg\n* Progressive neurological disease (multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, complex regional pain syndrome, acute herniating disc, severe spinal stenosis)\n* Certain comorbidities: coagulation\u002Fbleeding disorders, diminished capacity from cardiac\u002Fpulmonary disease\n* Obtaining another interventional procedure unrelated to SCS to treat limb pain\n* Have ongoing metastatic malignant neoplasm or untreated local malignant neoplasm. Included patients must be deemed as in remission per discretion of treating oncologist\n* Have a life expectancy of less than one year\n* Have untreated addiction or dependency to medications, alcohol, or illicit drugs\n* Have active, disruptive, and\u002For unstable psychological or psychiatric disorder",{"count":387,"type":20},20,"This study examines how spinal cord stimulation (SCS) affects pain level and quality of life in patients experiencing chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a nerve problem and one of the potential side effects of chemotherapy that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. CIPN usually begins in the hands or feet and gets worse over time. SCS is a type of therapy that has proven to be effective in treating numerous non-malignant pain disorders including failed back surgery syndrome, refractory angina, limb ischemia, complex regional pain syndrome, and diabetic peripheral neuropathy. SCS may also be useful in patients with CIPN. This study evaluates how SCS affects pain and quality of life in patients undergoing spinal cord stimulation for CIPN.",[390,26,27],"Chemotherapy-Induced Peripheral Neuropathy",{"date":392,"type":32},"2026-02-02",{"date":394,"type":32},"2022-04-14",{"date":396,"type":20},"2027-04-15",{"name":61,"class":39},{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":21,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":420,"locationsCount":164},"100400493","identifying-and-caring-for-individuals-with-inherited-cancer-syndrome-100400493","NCT04494945","Identifying and Caring for Individuals With Inherited Cancer Syndrome","Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes","Inclusion Criteria:\n\n* ALL COHORTS: 18 years of age or older\n* Retrospective COHORT A: Per HIPAA waiver, Retrospective Cohort A will not actively consent\n* Retrospective COHORT A: Patients may or may not be diagnosed with cancer\n* Retrospective COHORT A: Patients have received genetic counseling in the past 5 years\n* Retrospective COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and\u002For Lynch syndrome\n* COHORT A: Per Health Insurance Portability and Accountability Act (HIPAA) waiver, Cohort A returns survey as consent\n* COHORT A: Patients may or may not be diagnosed with cancer\n* COHORT A: Patients have received genetic counseling in the past 1 - 2 years\n* COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and\u002For Lynch syndrome\n* COHORT A: INCLUSIVE of no contact list to exclude from Cohort B\n* COHORT B: Creation of secure Healthy Oregon Project (HOP) app account\n* COHORT B: Consent to this project, either hard or electronic signature\n* COHORT B: Consent to the HOP repository, either hard or electronic signature\n* COHORT B: Choosing to submit a deoxyribonucleic acid (DNA) sample\n* COHORT B: Patients diagnosed with any National Cancer Institute (NCI)-reportable cancers, including ductal carcinoma in situ (DCIS) and\u002For in situ breast cancer\n* COHORT B: Must have had an encounter within past twelve months\n* COHORT B: Exclude Cohort A\n* COHORT C: Creation of secure Hop app account\n* COHORT C: Consent to this project, either hard or electronic signature\n* COHORT C: Consent to the HOP repository, either hard or electronic signature\n* COHORT C: Choosing to submit a DNA sample",{"count":406,"type":20},27500,[23],"This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.",[410,411,26,412,413,27],"BRCA1\u002F2-Associated Hereditary Breast and Ovarian Cancer Syndrome","Breast Ductal Carcinoma In Situ","Hereditary Neoplastic Syndrome","Lynch Syndrome","2026-01-21",{"date":416,"type":32},"2026-01-23",{"date":418,"type":32},"2020-03-09",{"date":239,"type":20},{"name":421,"class":39},"OHSU Knight Cancer Institute",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":21,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":40},"100364208","phase-1-bendamustine-with-or-without-cyclophosphamide-in-preventing-gvhd-in-patients-undergoing-stem-cell-transplant-100364208","NCT04022239","Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant","Post-Transplant Bendamustine (PT-BEN) for GVHD Prophylaxis","Inclusion Criteria:\n\n* Patient with hematologic malignancies.\n* Donor: Matched sibling, matched unrelated, mismatched or haploidentical\n* Zubrod performance 0 to 2 or Karnofsky of at least 60.\n* Adequate organ function at time of study entry:\n\n  1. Creatinine less than or equal to 1.6 mg\u002FdL and creatinine clearance \\>\u002F= 30 ml\u002Fmin. Creatinine clearance will be calculated using the Cockcroft-Gault equation\n  2. Total bilirubin less than \\\u003C 1.5 x UNL\n  3. SGPT \\\u003C 2.5 x ULN\n  4. Ejection fraction \\>\u002F= 40%\n  5. FEV1, FVC and DLCO \\>\u002F= 40%\n* Female patients of childbearing potential must agree to use an effective method of birth control while on study and for 6 months after the last dose of bendamustine. Male patients with female partners of childbearing potential must agree to use an effective method of birth control while on study and for 3 months after the last dose of bendamustine.\n\nExclusion Criteria:\n\n* Pregnant or nursing women.\n* Known to be HIV positive\n* Active and uncontrolled disease\u002Finfection\n* Unable or unwilling to sign consent\n* Current active hepatic or biliary disease (with exception of Gilbert's syndrome)\n* Active hepatitis B or C.\n* Toxicities (grade \\> 1) unresolved from prior treatment (including chemotherapy, targeted therapy, immunotherapy, experimental agents radiation, or surgery.\n* Patients with standard risk acute leukemia in first complete remission and patients with chronic myeloid leukemia in first chronic will be excluded during escalated phase.","70 Years",{"count":431,"type":20},25,[276,110],"This phase I\u002FII trial studies the side effects and best dose of bendamustine when given with or without cyclophosphamide in preventing graft versus host disease (GVHD) in patients undergoing stem cell transplant. Drugs used in chemotherapy, such as bendamustine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy and total body irradiation before or after a stem cell transplant helps kills cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Sometimes, the transplanted cells from a donor can attack the body's normal cells called GVHD. Giving tacrolimus, mycophenolate mofetil, and filgrastim after the transplant may stop this from happening.",[26],"2026-01-09",{"date":437,"type":32},"2026-01-12",{"date":439,"type":32},"2020-03-13",{"date":441,"type":20},"2027-07-31",{"name":291,"class":39},{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":21,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":40},"100498582","provider-mediated-communication-of-genetic-testing-results-to-at-risk-relatives-of-cancer-patients-to-improve-genetic-counseling-and-testing-rates-family-hope-study-100498582","NCT05772130","Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study","Family HOPE Study (Hereditary Lynch Syndrome Opportunities for Participation &Amp; Engagement)","Inclusion Criteria:\n\n* PATIENTS: Enrolled in City of Hope (COH) institutional review board (IRB) 07047 or have been seen by COH Genetics for genetic testing\n* PATIENTS: Have an pathogenic\u002F likely pathogenic germline variant\n* PATIENTS: Fluent in English\n* PATIENTS: Age \\>= 18 years\n* PATIENTS: Willing to provide contact information for eligible first-degree relatives\n* PATIENTS: \\>= 2 first-degree relatives that are eligible for genetic testing and reside in the United States of America\n* FIRST-DEGREE RELATIVES: Proband is a COH patient and has consented to this study\n* FIRST-DEGREE RELATIVES: First-degree relative of proband\n* FIRST-DEGREE RELATIVES: Resides within the United States\n* FIRST-DEGREE RELATIVES: Has not undergone genetic testing for the known familial variant\n* FIRST-DEGREE RELATIVES: Are fluent in English\n* FIRST-DEGREE RELATIVES: Age \\>= 18 years\n\nExclusion Criteria:\n\n* PATIENTS: Unable to provide informed consent\n* PATIENTS: =\\\u003C 2 at-risk first-degree relatives who are eligible for genetic testing and\u002For reside within the United States\n* PATIENTS: Unwilling to provide contact information for family members\n* FIRST-DEGREE RELATIVES: Unable or unwilling to provide informed consent\n* FIRST-DEGREE RELATIVES: Have undergone genetic testing for the known familial variant\n* FIRST-DEGREE RELATIVES: Resides outside of the United States",{"count":451,"type":20},240,[23],"This clinical trial tests whether provider-mediated communication of genetic testing results to at-risk relatives of cancer patients can help improve genetic counseling and testing rates. Approximately 15% of people with cancer have an inherited form of cancer due to changes in a gene that they have inherited from one of their parents. These changes increase a person's risk for developing cancer. Most people who have an inherited harmful change in a cancer risk gene don't know that they have it and are therefore not able to get the health care that they need. The primary reason for this problem has been a lack of genetic counseling and testing for cancer patients and patients with a strong family history of cancer. Another reason for this lack of awareness is that, when cancer runs in a family, the patient who carries the gene change usually has to communicate the genetic risk information to their family members. When this process doesn't work well, family members may not know that they need to get genetic testing and then may not get potentially life-saving care. Provider-mediated contact to discuss genetic test results may help improve rates of genetic testing among at-risk relatives of patients with a family cancer syndrome.",[26,455,27],"Hereditary Malignant Neoplasm","2025-12-31",{"date":458,"type":32},"2026-01-05",{"date":460,"type":32},"2023-02-14",{"date":462,"type":20},"2026-12-21",{"name":335,"class":39},{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":21,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":40},"100531981","community-based-physical-activity-intervention-for-underserved-cancer-survivors-100531981","NCT06206863","Community-Based Physical Activity Intervention for Underserved Cancer Survivors","Community-Based Physical Activity Across the Cancer Continuum","Inclusion Criteria:\n\n* Have had a previous cancer diagnosis OR are a caregiver for a patient who has had a previous cancer diagnosis\n* Not in active treatment for cancer\n* Over 18 years of age\n\nExclusion Criteria:\n\n* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, atrial fibrillation (AFIB), multiple myeloma, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Have orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise\n* Are pregnant or nursing\n* Are unwilling or unable to follow protocol requirements\n* Have any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study",{"count":88,"type":20},[23],"This clinical trial evaluates a community-based physical activity program for underserved cancer survivors. Cancer and its treatment significantly influence physical, psychosocial, and cognitive functioning. Historically, community sites (local and national) have not been staffed to offer support services such as physical, and occupational therapies (everyday life activities to promote health and well-being) or nutrition counselling, and do not offer a whole-person model of care. In this study, researchers have partnered with the YMCA to provide tailored home-based exercise programs for underserved cancer patients and survivors. Accessing exercise professionals may allow patients to prevent acute problems from becoming chronic, long-lasting physically weak impairments that directly influence patients' quality of life.",[26,27],"2025-12-08",{"date":477,"type":32},"2025-12-16",{"date":479,"type":32},"2024-08-20",{"date":481,"type":20},"2027-12-30",{"name":483,"class":39},"Roswell Park Cancer Institute",{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":21,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":40},"100507941","low-intensity-mechanical-stimulation-for-hematologic-malignancy-patients-100507941","NCT05893940","Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients","Inclusion Criteria:\n\n* COHORT I: Meet eligibility criteria for first autologous or allogeneic HCT (patients with preexisting osteoporosis are eligible)\n* COHORT I: Scheduled to undergo an autologous or allogeneic HCT\n* COHORT 1: \\>= 18 years of age\n* COHORT 1: Patient must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure\n\n  \\- COHORT II: ≥ 18 years of age\n* COHORT II: Diagnosis of non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia; patients with preexisting osteoporosis are eligible)\n* COHORT II: Patient must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\nCOHORT 1:\n\n* Any prior allogeneic HCT\n* Any prior autologous HCT for those patients who have a planned auto HCT\n* Pre-transplant weight \\>= 275 lbs. (max weight for the board)\n* Body mass index (BMI) \\\u003C 18 kg\u002Fm\\^2\n* Recipient of cord blood transplant\n* Multiple myeloma or amyloidosis diagnosis\n* History of a central nervous system (CNS) hemorrhage \\\u003C 60 days\n* History of any aneurysm (cerebral, aortic, etc.)\n* A recent pulmonary embolism or deep vein thrombosis\n* A cardiac pacemaker\n* Prior history of non-traumatic (spontaneous) fracture\n* Total joint replacement (any joint)\n* History of kidney stones or gall stones within the last 2 years unless a cholecystectomy was performed\n* Any prosthetic lower extremity or limb\n* Pregnant or nursing female patients\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study intervention\n\nCOHORTII:\n\n* Planned CAR T-cell therapy within the next 2 months\n* Prior CAR T-cell therapy\n* Active treatment within the last 60 days\n* Pre-transplant weight ≥ 275 lbs. (max weight for the board)\n* BMI \\\u003C 18 kg\u002Fm\\^2\n* History of a CNS hemorrhage \\\u003C 60 days\n* History of any aneurysm (cerebral, aortic, etc.)\n* A recent pulmonary embolism or deep vein thrombosis\n* A cardiac pacemaker\n* Recent history (\\\u003C 60 days) of non-traumatic (spontaneous) fracture\n* Recent surgery (\\\u003C 60 days)\n* Pregnant or nursing female patients\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study intervention",{"count":491,"type":20},75,[23],"This clinical trial tests the effect of low-intensity mechanical stimulation (LIMS) vibration therapy in patients with hematologic malignancies. Patients with hematologic malignancies often undergo a blood and\u002For bone marrow transplant (hematopoietic cell transplantation \\[HCT\\]) or cellular therapy. The LIMS board delivers vibrations through the bones that may stimulate bone growth and may also increase muscle activity and strength and may also increase T-cell activation in patients planning to undergo cellular therapy. LIMS vibration therapy may stop or reverse BMD loss and\u002For improve the development of T-cells in the body in patients with hematologic malignancies who are undergoing or may plan to undergo HCT or cellular therapies.",[26],"2025-12-02",{"date":497,"type":32},"2025-12-03",{"date":499,"type":32},"2023-08-14",{"date":501,"type":20},"2026-09-01",{"name":483,"class":39},{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":11,"sex":17,"minAge":510,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":21,"phases":512,"briefSummary":513,"conditions":514,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":187},"100517855","telemedicine-for-improvement-of-care-for-older-adults-with-cancer-in-the-underserved-community-the-gain-s-trial-100517855","NCT06022965","Telemedicine for Improvement of Care for Older Adults With Cancer in the Underserved Community, The GAIN-S Trial","Geriatric Assessment (GA)-Driven Interventions With Supportive Care (The GAIN-S Trial): Telemedicine to Increase Goal Concordant Care for Older Adults With Cancer in the Community","Inclusion Criteria:\n\n* Documented informed consent of the participant.\n* Patient's physician must agree for patient participation.\n* Ability to read English, Spanish, or Chinese. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available, and language does not preclude completing study procedures.\n* Age: \\>=65 years at the time of enrollment.\n* Diagnosis of stage I-IV cancer.\n* Scheduled to start a new therapy (chemotherapy, immunotherapy, or targeted therapy).\n\nExclusion Criteria:\n\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).","65 Years",{"count":319,"type":20},[23],"This clinical trial evaluates whether geriatric assessment-driven interventions with supportive care (GAIN-S) using telemedicine can be used to identify areas of vulnerability (weakness) in older adults with cancer and guide interventions to assist the patient and the healthcare team in the underserved community. The majority of patients diagnosed with cancer are over age 65 years, yet most cancer treatments are developed and tested in a younger population. Therefore, older patients with cancer are less likely to be offered standard treatments because of the concern regarding side effects. Geriatric assessment (GA) is a multi-dimensional health assessment tool combining patient reported and objective (unbiased) results. There is no standard tool that can identify which older adults will be more likely to have side effects from cancer treatment. Telemedicine is a way to provide healthcare services (including consultations, education, care management and treatment) in which the health care provider is at a distant site. The goal of this project is to use telemedicine to identify areas of vulnerability\u002Fweakness in older adults with cancer using a patient assessment, and to identify the potential referrals to a multi-specialty team based on patient assessment results. Information gathered from this study may help researchers learn whether GAIN-S can be performed using telemedicine and lead to improvement in care for older adults compared to standard of care (SOC) in the underserved community.",[26,27],"2025-10-02",{"date":517,"type":32},"2025-10-06",{"date":519,"type":32},"2023-07-24",{"date":521,"type":20},"2027-01-24",{"name":335,"class":39},{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":21,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":40},"100473325","phase-1-leflunomide-in-combination-with-steroids-for-the-treatment-of-acute-graft-versus-host-disease-after-donor-stem-cell-transplant-for-hematologic-malignancies-100473325","NCT05443425","Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies","Pilot Trial of Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Age \\>= 18 years old\n* Karnofsky performance status \\>= 70\n* Clinically suspected grade II-IV aGvHD based on Mount Sinai Acute GVHD International Consortium (MAGIC) Consensus criteria occurring after allogeneic hematopoietic cell transplantation (HCT) and GvHD prophylaxis regimen. Grade I acute (a)GvHD requiring systemic steroids is allowed. Clinical suspicion of aGvHD by the treating physician is sufficient, provided that alternative diagnosis of drug effects or infection are adequately ruled out\n\n  * Note: HCT from any donor (related or unrelated with any degree of human leukocyte antigen \\[HLA\\] matching) and any graft source (bone marrow, peripheral blood stem cells, or cord blood) for hematologic malignancy or disorder. Recipient of myeloablative and reduced-intensity conditioning regimens are eligible\n* Biopsy of acute GvHD target organ is recommended but not required. Enrollment should not be delayed for biopsy or pathology results. Patients who do not enroll within 72 hours from start of steroids are not permitted to participate\n* Evidence of myeloid engraftment (e.g., absolute neutrophil count \\[ANC\\] \\>= 0.5 x 10\\^9\u002FL for 3 consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed\n* No prior systemic treatment for treatment of acute GvHD except for a maximum of 72 hours of prednisone =\\\u003C 2 mg\u002Fkg\u002Fday (or intravenous \\[IV\\] methylprednisone equivalent). Topical skin steroid treatment and non-absorbable oral steroid treatment for GI GvHD are permissible\n* Patients should be able to swallow and retain oral medication\n* Total bilirubin =\\\u003C 2 X ULN (unless has Gilbert's disease or aGvHD within 3 days of enrollment) (performed within 14 days prior to day 1 of protocol therapy)\n* Aspartate aminotransferase (AST) =\\\u003C 3 x upper limit of normal (ULN) (performed within 14 days prior to day 1 of protocol therapy)\n* Alanine aminotransferase (ALT) =\\\u003C 3 x ULN (performed within 14 days prior to day 1 of protocol therapy)\n* Creatinine clearance of \\>= 50 mL\u002Fmin per 24-hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy)\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Recipient of more than one allogeneic HCT\n* Received more than 3 days of systemic corticosteroid for treatment of aGvHD\n* Presence of GVHD overlap syndrome\n* Prior treatment with leflunomide\n* Current or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment period\n* Use of other drugs for treatment of acute GvHD\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent (leflunomide or cholestyramine)\n* Clinically significant uncontrolled illness\n* Patients on dialysis\n* Patient requiring ventilator support\n* Presence of an active uncontrolled infection. An active uncontrolled infection is defined as hemodynamic instability attributed to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without signs or symptoms will not be interpreted as an active uncontrolled infection\n* Known history of immunodeficiency virus (HIV) infection\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment, HBV deoxyribonucleic acid (DNA) and HCV ribonucleic acid (RNA) must be undetectable upon testing. Prior test results obtained as part of standard of care that confirm a subject is immune and not at risk for reactivation (i.e., hepatitis B surface antigen negative, surface antibody positive) may be used for purpose of eligibility and test do not need to be repeated. Subjects within prior positive serology results must have negative polymerase chain reaction results. Subjects whose immune status is unknown must have results confirming immune status before enrolment\n* Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allogeneic (allo)-HCT was performed\n* Severe organ dysfunction unrelated to underlying GvHD, including:\n\n  * Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GvHD and ongoing organ dysfunction)\n  * Clinically significant uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months of enrollment, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy\n  * Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen\n* Non-hematologic malignancy within the past 3 years aside from the following exceptions:\n\n  * Adequately treated basal cell or squamous cell skin cancer\n  * Carcinoma in situ of the cervix\n  * Prostate cancer \\\u003C Gleason Grade 6 with a stable prostate specific antigen (PSA)\n  * Successfully treated in situ carcinoma of the breast\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures. e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, social\u002F psychological issues, etc.\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":531,"type":20},18,[276],"This phase I trial tests the safety and side effects of leflunomide in combination with steroids in treating patients with acute graft versus host disease who have undergone done stem cell transplant for blood cancers (hematologic malignancies). Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Leflunomide and steroids are immunosuppressive drugs that work in different ways to lower the body's immune response so that the new donor immune cells do not attack the body's normal cells. Giving leflunomide in combination with steroids may help treat acute graft versus host disease in patients after stem cell transplant for hematologic malignancies.",[535,26],"Acute Graft Versus Host Disease","2025-07-02",{"date":538,"type":32},"2025-07-04",{"date":540,"type":32},"2023-06-16",{"date":542,"type":20},"2027-01-05",{"name":335,"class":39}]